

AMENDMENTS TO THE CLAIMS

A detailed listing of all claims that are, or were, in the present application, irrespective of whether the claim(s) remains under examination in the application are presented below. The claims are presented in ascending order and each includes one status identifier. Those claims not cancelled or withdrawn but amended by the current amendment utilize the following notations for amendment: 1. deleted matter is shown by strikethrough; and 2. added matter is shown by underlining.

- 24
1. [Cancelled] 7
 2. [Cancelled]
 3. [Cancelled]
 4. [Cancelled]
 5. [Cancelled]
 6. [Cancelled]
 7. [Cancelled]
 8. [Cancelled]
 9. [Cancelled]
 10. [Cancelled]
 11. [Cancelled]
 12. [Cancelled]
 13. [Cancelled]
 14. [Cancelled]
 15. [Cancelled]

16. [Cancelled]

17. [Cancelled]

18. [Cancelled]

19. [Cancelled]

20. [Cancelled]

21. [Cancelled]

22. [Cancelled]

23. [Cancelled]

24. [Cancelled]

25. [Cancelled]

26. [Cancelled]

27. [Cancelled]

28. [Cancelled]

29. [Cancelled]

30. [Cancelled]

31. [Cancelled]

32. [Cancelled]

33. [Cancelled]

34. [Cancelled]

35. [Cancelled]

36. [Cancelled]

37. [Cancelled]

38. [Cancelled]

39. [Cancelled]

40. [Currently Amended] A method of transplanting pancreatic islet cells from a donor to a recipient, the method comprising:

Cf ~~administering~~ transplanting a pancreatic islet cell ~~transplant~~ from the donor to the recipient; and

inducing a state of mixed chimerism in the recipient according to a method that includes:

infusing donor cells within 96 hours of the pancreatic islet cell transplant from the donor into the recipient, the donor cells causing the production of immune system cells in the recipient that have at least one cellular marker that is characteristic of the donor immune system;

administering a conditioning treatment to the recipient that is mildly myeloablative; and

administering an immune blockade treatment to the recipient.

41. [Previously Added] The method of claim 40, wherein the donor cell infusion and the pancreatic islet cell transplant both occur within a twelve hour time period.

42. [Previously Added] The method of claim 40, wherein the state of mixed chimerism is such that a donor chimerism level in the recipient of at least 15% is achieved as determined by measurements taken from the recipient's peripheral blood samples.

43. [Previously Added] The method of claim 40, further comprising administering a cell pretreatment from the donor to the recipient prior to the infusion of the donor cells.

44. [Previously Added] The method of claim 43, further comprising administering an antilymphocyte serum within 48 hours after an end of the cell pretreatment.

45. [Cancelled]

46. [Cancelled]

47. [Cancelled]

48. [Cancelled]

49. [Cancelled]

50. [Cancelled]

51. [Cancelled]

52. [Cancelled]

53. [Cancelled]

54. [Cancelled]

55. [Cancelled]

56. [Cancelled]

57. [Cancelled]

58. [Cancelled]


59. [Cancelled]

60. [Cancelled]

61. [Cancelled]

62.  [Cancelled]

63. [Cancelled]

64.  [Cancelled]

65. [Previously Added] The method of claim 40, wherein the donor is a clinical cadaver and the pancreatic islet cell transplant, conditioning treatment, and the infusion of the donor cells are completed within a single continuous forty-eight hour period of time.

66. [Previously Added] The method of claim 40, wherein the conditioning treatment is accomplished such that an amount of granulocytes in the recipient's blood decreases by less than 30%.

C.4 67. [Previously Added] The method of claim 40, wherein the donor cell infusion is performed after the pancreatic islet cell transplant.

68. [Previously Added] The method of claim 40, further comprising pretreating the recipient with pretreatment cells from the donor prior to the infusion of the donor cells.

69. [Previously Added] The method of claim 40, wherein the conditioning treatment is accomplished by administering at least one drug chosen from the group consisting of fludarabine phosphate, busulfan, and cyclophosphamide.

70. [Previously Added] The method of claim 40, wherein administering the conditioning treatment is accomplished by administering at least one drug chosen from the group consisting of a purine nucleoside analog, deoxycoformycin, 2-chloro-2' deoxyadenosine, ifosamide, etoposide,

mitoxantrone, doxorubicin, cisplatin, carboplatin, cytarabine, paclitaxel, nitrosoureas, melphalan, thiotepa, antilymphocyte serum, anti-thymocyte globulin, and anti-lymphocyte globulin.

71. [Previously Added] The method of claim 40, wherein administering the immune blockade treatment is accomplished by administering at least one of the compounds selected from the group consisting of anti-CD40L, sirolimus, CTLA4Ig, LEA29Y, and compounds that inhibit the binding of B7 to CD28.

72. [Previously Added] The method of claim 40, wherein the conditioning treatment is started less than six days prior to the infusion of the donor cells.

C. 73. [Previously Added] The method of claim 40, wherein the conditioning treatment is started less than two days prior to the infusion of the donor cells.

74. [Previously Added] The method of claim 40, wherein the donor cell infusion is performed by administering bone marrow from the donor to the recipient.

75. [Previously Added] The method of claim 40, wherein the donor cell infusion is performed by administering stem cells to the recipient.

76. [Previously Added] The method of claim 75, wherein the donor cell infusion includes administering the stem cells to the recipient on more than one day.

77. [Previously Added] The method of claim 40, wherein the donor cell infusion includes administering stem cells to the recipient that are collected from the peripheral blood of the donor.

78. [Previously Added] The method of claim 40, wherein the conditioning treatment includes low-dose irradiation of less than 500 GY.

CF 79. [Currently Amended] The method of claim 40 78, wherein the conditioning treatment includes a low-dose total body irradiation of less than 300 GY.
